Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 61 results found. Search for [ compulsory licence ]

Results 40 to 60 of 61
Anand Adhikari
June 3, 2013
The central bank has extended the validity period of the in-principle approval for setting up a bank from one year to 18 months.


E. Kumar Sharma
April 13, 2013
The Supreme Court decision on Glivec sets the tone for other patent disputes and puts global drugmakers on the back foot.


E Kumar Sharma
April 1, 2013
The Supeme Court has refused protection for Novartis' blood cancer drug Glivec on the grounds that it is not a new medicine but only an amended version of a known compound.


BT Online Bureau
March 7, 2013
Bayer AG  will approach the high court in Mumbai against a ruling by Intellectual Property Appellate Board that upheld the compulsory licence issued to India's Natco Pharma to make and sell a low-cost generic of the German drug major's patented cancer drug Nexavar.


Associated Press
New Delhi, March 5, 2013
The Intellectual Property Appellate Board has rejected Bayer AG's plea to stop Natco Pharma from producing a cheaper generic version of its patented cancer drug.


E. Kumar Sharma
November 29, 2012
The Intellectual Property Appellate Board's decision to deny patent protection to AstraZeneca for its lung cancer drug Gefitinib is the latest setback for global pharmaceutical companies in India.


BT Online Bureau
New Delhi, November 29, 2012
Intellectual Property Appellate Board (IPAB) has again turned down drug firm AstraZeneca's plea for a patent on the lung cancer drug Gefitinib.


E. Kumar Sharma
November 4, 2012
India's Intellectual Property Appellate Board has revoked the patent granted in India to F. Hoffmann-La Roche AG (Roche) for pegylated interferon alfa-2a, a medicine used to treat hepatitis C, citing lack of evidence that the drug was better than existing treatments available in the market.


Team BT
October 9, 2012
Of late, the heads of a number of regulatory bodies have been flexing their muscles in different ways, using the full extent of their powers in a manner their predecessors had never done.


PTI
New Delhi, August 30, 2012
The Comptroller and Auditor General (CAG) has criticised autonomous body BIS for lagging behind in achievement of targets fixed for grant of licences to jewellers under the voluntary gold hallmarking scheme.


PTI
Berlin, May 10, 2012
Bayer holds the patent for Nexavar till 2020 and it will \"vigorously defend its patent within the available legal framework\".


PTI
New Delhi, May 7, 2012
In March this year, India had invoked a law permitting Hyderabad-based Natco Pharma to manufacture and sell cancer-treatment drug Nexavar at a price over 30 times lower than charged by its patent-holder Bayer Corporation.


E Kumar Sharma
Hyderabad, May 4, 2012
Cipla says that its decision to slash prices of cancer drugs is purely a humanitarian gesture. In cancer treatment, it is planning to do what it did in anti-AIDS drugs many years ago by launching them at low prices.


www.businesstoday.in
March 29, 2012
Business Today's E Kumar Sharma talks about the challenges facing the increasingly competitive pharmaceutical industry, and what compulsory licensing can and can't do for India's poor.


Dinesh C. Sharma
New Delhi, March 28, 2012
The landmark decision of the patent office to break the monopoly of Bayer in kidney and liver cancer drugs recently is already having a rippling effect.


Chaitanya Kalbag
March 28, 2012
Caprice and cowardice were both on display last fortnight. Ten days after a bunch of state election results delivered a hard punch in the Congress party's solar plexus, Pranab Mukherjee delivered a Budget for 2012/13 that was simultaneously retrograde and revanchist.


E. Kumar Sharma
March 27, 2012
Compulsory licences have brought domestic and multinational pharma companies face to face. Although domestic firms are getting to make cheaper versions of patented drugs, will this be enough to cure the country of its health care ills?


E Kumar Sharma
March 13, 2012
This is the first time an Indian company has been granted a compulsory licence, which means the patent holders grant licences to generic drug makers.


Manasi Mithel
March 19, 2012
Home to the highest concentration of makers of generic drugs, India has been a global source of cheap medicines. But seven years into the product patent regime, affordable access to some lifesaving drugs remains an issue.


Tanvi Varma/Money Today
June 6, 2011
H N Sinor, CEO, Association of Mutual Funds of India, tells Tanvi Varma that mutual funds should be viewed more as 'investment managers'.


PAGES 3 OF 4  1234